14Sep/21
A strategic partnership worthy of 2.45 billion dollars reached between Pfizer and Arvinas to develop PROTAC protein degradants against ER+ breast cancer!
Recently, Pfizer and Arvinas announced a partnership to develop and commercialize ARV-471, an oral PROTAC estrogen receptor protein degrader under development. Estrogen receptor (ER) is a well-known disease driver in most breastRead More…